Elite in Hereditary Alpha-Tryptasemia

Patrizia Bonadonna

Verona, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Hereditary Alpha-Tryptasemia
Verona, IT 
OverviewLocationsClinical Research

Overview

Patrizia Bonadonna practices in Verona, Italy. Ms. Bonadonna is rated as an Elite expert by MediFind in the treatment of Hereditary Alpha-Tryptasemia. Her top areas of expertise are Mast Cell Activation Syndrome (MCAS), Systemic Mastocytosis, Anaphylaxis, and Hereditary Alpha-Tryptasemia.

Her clinical research consists of co-authoring 144 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 8 articles in the study of Hereditary Alpha-Tryptasemia.

Gender
Female

Locations

Verona, Italy
Other Locations
Vicenza, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
Enrollment Status: Recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drug: BLU-263
Study Phase: Phase 2/Phase 3
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
View 1 Less Clinical Trial

144 Total Publications

Comparison of Allergic Rhinitis Treatments on Patient Satisfaction: A MASK-air and EAACI Methodological Committee Report.
Comparison of Allergic Rhinitis Treatments on Patient Satisfaction: A MASK-air and EAACI Methodological Committee Report.
Journal: Allergy
Published: May 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Bonadonna's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile